TNFRSF17 and Miyoshi myopathy: B-cell maturation antigen (BCMA) essential for the long-term survival of plasma cells is highly expressed on the malignant plasma cells in multiple myeloma (MM) with almost no expression on normal cells, which can be the promising target for T-cell based immunotherapy [57].